06 October 2023
06 October 2023
Mitokinin focuses on the development of disease-modifying therapies for Parkinson’s disease.
In May 2023, GSK offloaded 240 million ordinary shares in Haleon for $1bn.
Forxiga has approval for adult use in 122 countries and in the EU to treat paediatric patients for T2D above the age of ten.
Orchard's portfolio includes Libmeldy, which has been approved for a rare genetic disorder, metachromatic leukodystrophy.
The company has commenced the STENOVA Phase IIa clinical study to assess AGMB-129 for symptomatic FSCD.
Twist will receive $188m in clinical and commercial milestone payments and royalties from the deal.
EMA gives positive opinion for granting Calliditas Therapeutics’ Alport syndrome drug an orphan designation.
The Excellence Awards celebrate the greatest achievements and innovations in the industry, and the people and companies that are driving change.
With only a few approved drugs currently available to treat DN by means other than regulation of blood pressure, innovator products that can treat by targeting other factors such as treatment of dyslipidemia, hypertension, or angiotensin inhibition, among others, is a key area of R&D in the DN space and is likely to pave the way for novel therapies in the near future. However, the treatment landscape is expected to remain unchanged due to limited availability of products in the late-stage pipeline currently.
Give your business an edge with our leading industry insights.
